Logos Global Management’s Aclaris Therapeutics ACRS Stock Holding History

Logos Global Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Sell	200,000 -300,000	-60%	-$1.34M	0.05%	64
2026 Q1	$1.88M	Sell	500,000 -100,000	-17%	-$337K	0.09%	61
2025 Q4	$1.81M	Sell	600,000 -900,000	-60%	-$2.27M	0.11%	64
2025 Q3	$2.85M	Sell	1,500,000 -350,000	-19%	-$610K	0.26%	52
2025 Q2	$2.63M	Sell	1,850,000 -372,222	-17%	-$504K	0.29%	47
2025 Q1	$3.4M	Hold	2,222,222	–	–	0.6%	29
2024 Q4	$5.51M	Buy	+2,222,222	New	+$5.53M	0.64%	35
2023 Q3	–	Sell	-525,000	Closed	-$5.44M	–	58
2023 Q2	$5.44M	Buy	+525,000	New	+$4.75M	0.74%	38
2021 Q3	–	Sell	-675,000	Closed	-$11.9M	–	58
2021 Q2	$11.9M	Buy	+675,000	New	+$15.3M	1%	30

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Logos Global Management's ACRS Position: Q2 2026 in Review

Logos Global Management reduced its Aclaris Therapeutics (ACRS) stake by 60% in Q2 2026, selling an estimated $1.34M and leaving 200,000 shares worth $1.06M. The position accounts for 0.05% of the portfolio, ranked #64.

Logos Global Management first reported a position in ACRS in Q2 2021 and has held it in 9 quarters since. The position peaked at $11.9M in Q2 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Logos Global Management held 200,000 shares of Aclaris Therapeutics worth $1.06M as of Q2 2026.
Logos Global Management sold 300,000 Aclaris Therapeutics shares in Q2 2026, an estimated $1.34M.
Aclaris Therapeutics made up 0.05% of Logos Global Management's portfolio in Q2 2026, its #64 holding.
Logos Global Management first reported a position in Aclaris Therapeutics in Q2 2021 and has held it in 9 quarters since.
Logos Global Management's Aclaris Therapeutics position peaked at $11.9M in Q2 2021.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.